Status:
RECRUITING
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
Lead Sponsor:
Mayo Clinic
Conditions:
PreDiabetes
Eligibility:
All Genders
25-70 years
Phase:
PHASE2
Brief Summary
We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounce...
Detailed Description
We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. This supports other evidence (ro...
Eligibility Criteria
Inclusion
- People with stable weight and no history of diabetes.
- Fasting glucose \< 126 mg/dL
- 2hr glucose after 75g OGTT \< 200 mg/dL
Exclusion
- Age \< 25 or \> 70 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
- HbA1c \> 6.5%
- Use of any glucose-lowering agents including metformin or sulfonylureas.
- For female subjects: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06967558
Start Date
November 1 2025
End Date
March 31 2028
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905